Sorrento’s R&D is focused on driving innovation in COVID-19, cancer treatment, full pain control and autoimmune diseases

Portfolio	Key Programs	Indication	Preclinical	Phase I	Phase II	Phase III/Pivotal	FDA Approval
COVID-19 Programs	COVI-TRACE™ Diagnostic Test 0%* FDA Emergency Use Authorization (EUA) Application Expected COVI-TRACK™ Antibody Test 0%* FDA Emergency Use Authorization (EUA) Application Under Review COVI-GUARD™ Neutralizing Antibody 30%* COVI-AMG™ Neutralizing Antibody 10%* COVI-SHIELD™ Antibody Cocktail 10%* COVIDTRAP™ ACE2 Receptor Decoy 10%* T-VIVA-19™ Vaccine 10%* ABIVERTINIB Cytokine Storm 55%*
Immunotherapy	CD38 CAR-T Multiple Myeloma 30%* CD38 DAR-T Multiple Myeloma 10%* CD38 ADC Amyloidosis 30%* Seprehvir™ Solid Tumors 30%* ABIVERTINIB NSCLC 80%* ADNIC Solid and Liquid Tumors 55%*
Pain	RTX (resiniferatoxin) Epidural route Terminal Cancer Pain 55%* Orphan designation RTX (resiniferatoxin) Intra-articular route Moderate to Severe OA 55%* RTX (resiniferatoxin) Intra-articular route TKR Deferment 55%*
Lymphatic Delivery	Sofusa® anti-TNF Autoimmune 30%* Sofusa® anti-PD-1 CTCL 30%*

COVID-19 Programs
Key Programs (Indication)	Phase
COVI-TRACE™ (Diagnostic Test) FDA EUA COVI-TRACK™ (Antibody Test) FDA EUA COVI-GUARD™ Ph I COVI-AMG™ Preclinical COVI-SHIELD™ Preclinical COVIDTRAP™ Preclinical T-VIVA-19™ (Vaccine) Preclinical ABIVERTINIB (Cytokine Storm) Ph II

Immunotherapy
Key Programs (Indication)	Phase
CD38 CAR-T (Multiple Myeloma) Ph I CD38 DAR-T (Multiple Myeloma) Preclinical CD38 ADC (Amyloidosis) Ph I Seprehvir™ (Solid Tumors) Ph I ABIVERTINIB (NSCLC) PhIII/Pivotal ADNIC (Solid and Liquid Tumors) Ph II

Pain
Key Programs (Indication)	Phase
RTX (resiniferatoxin) Epidural route (Terminal Cancer Pain) Ph II RTX (resiniferatoxin) Intra-articular route (Moderate to Severe OA) Ph II RTX (resiniferatoxin) Intra-articular route (TKR Deferment) Ph II

Lymphatic Delivery
Key Programs (Indication)	Phase
Sofusa® anti-TNF (Autoimmune) Ph I Sofusa® anti-PD-1 (Immuno Oncology) Ph I